Kelly Marcello
Family · Phoenix, AZNPI 1699270462
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 43.5% of the total. 2025 is the largest year on record at $13,527, more than ten times the $266 reported in 2021. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $110.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$10K
- Merck$9K
- United Therapeutics Corporation$2K
- AstraZeneca$321
- Boehringer Ingelheim$311
- Johnson & Johnson$257
- plus $1K from 18 others
What the payments were for
- Consulting fees$6,37327%
- Speaking & faculty fees$2,73012%
- Travel & lodging$4,70720%
- Food & beverage$9,30440%
- Education$2151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 73 | $10,139 |
| Merck | 34 | $8,678 |
| United Therapeutics Corporation | 35 | $2,166 |
| AstraZeneca | 9 | $321 |
| Boehringer Ingelheim | 12 | $311 |
| Johnson & Johnson(2 entities) | 3 | $257 |
| Bayer | 2 | $218 |
| Liquidia Technologies, Inc. | 2 | $189 |
| Amgen | 3 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $125 |
| AbbVie | 1 | $107 |
| Baxter Healthcare | 5 | $92 |
| Vifor Pharma, Inc. | 3 | $89 |
| Grifols USA, LLC | 3 | $81 |
| Sanofi | 4 | $73 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Astellas Pharma US Inc | 2 | $51 |
| Sandoz | 3 | $50 |
| Insmed, Inc. | 2 | $41 |
| Philips North America LLC | 2 | $36 |
| Shionogi Inc | 2 | $34 |
| Viatris Specialty LLC | 1 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,329 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 29 | $731,858 |
| Tyvaso DpiTreprostinil | 18 | $453,871 |
| OpsumitMacitentan | 17 | $214,853 |
| AdempasRiociguat | 14 | $197,228 |
| OfevNintedanib Esylate | 13 | $184,497 |
| Orenitram ErTreprostinil Diolamine | 12 | $26,708 |
| Tadalafil | 19 | $22,720 |
| OzempicSemaglutide | 13 | $17,428 |
| EntrestoSacubitril/Valsartan | 20 | $15,899 |
| EliquisApixaban | 11 | $6,408 |
| Sildenafil Citrate | 22 | $2,373 |
| Mycophenolate Mofetil | 11 | $957 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $546 |
| Rosuvastatin Calcium | 11 | $544 |
| Prednisone | 33 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $10,139 | $946,71146 claims |
| BayerAdempas | $218 | $197,22814 claims |
| Boehringer IngelheimOfev | $311 | $184,49713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
- Susan HawrylkiwPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.